Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population.
Eva Fernandez-DiazJose A Perez-VicenteRamon Villaverde-GonzalezLeticia Berenguer-RuizAntonio Candeliere MerliccoMaria Luisa Martinez-NavarroJulia Gracia GilCarlos M Romero-SanchezArantxa Alfaro-SaezInmaculada DiazJuana Gimenez-MartinezMaria Angeles Mendez-MirallesJorge Millan-PascualJavier Jimenez-PanchoSantiago MolaÁngel Pérez SemperePublished in: Annals of clinical and translational neurology (2020)
The preliminary results in our real-world setting show that ocrelizumab presented excellent results in suppressing disease activity with a favorable and consistent safety profile.